Expression and clinical significance of chemokine CXCL10 and its receptor CXCR3 in hepatocellular carcinoma

  • Jing ZHANG ,
  • Jie CHEN ,
  • Gui-wen GUAN ,
  • Ting ZHANG ,
  • Feng-min LU ,
  • Xiang-mei CHEN
Expand
  • Department of Microbiology & Infectious Disease Center, Peking University School of Basic Medical Sciences, Beijing 100191, China

Received date: 2019-03-25

  Online published: 2019-06-26

Supported by

Supported by Beijing Natural Science Foundation(7182079)

Abstract

Objective: To explore the expression and clinical significance of chemokine CXCL10 and CXCR3 in hepatocellular carcinoma (HCC).Methods: The expression and prognostic of CXCL10 and CXCR3 in HCC tumor tissues and non-tumor tissues were analyzed in two different publicly available databases the Cancer Genome Atlas (TCGA) and Liver Cancer Institute (LCI). In addition, quantitative real-time PCR (qPCR) was used to detect the mRNA expression of CXCL10 and CXCR3 in 45 HCC cli-nical samples with HBV infection background. Pearson correlation and Spearman rank correlation were used to determine the correlation between the expression level of CXCL10 and CXCR3 in tumor and non-tumor tissues. Results: In TCGA database, the expression of CXCL10 in HCC tumor tissues was significantly higher than that in non-tumor tissues (nonpaired samples: 3.379±2.081 vs. 2.213±2.274, P<0.001; paired samples: 3.159±2.267 vs. 2.213±2.274, P=0.018). Similarly in LCI datebase (7.625±1.683 vs. 7.287±1.328, P=0.009). And higher CXCL10 expression was significantly associated with a better prognosis in the patients with HCC both in TCGA and LCI database (P=0.107, P=0.002). In TCGA database, the expression of CXCR3 in HCC tumor tissues was significantly higher than that in non-tumor tissues (nonpaired samples: -0.906±1.697 vs. -1.978±1.629, P<0.001; paired samples: -1.329±1.732 vs. -1.978±1.629, P=0.037), while lower in LCI database (3.989±0.339 vs. 4.074±0.309, P=0.003). In both databases, higher CXCR3 expression was significantly associated with a better prognosis in the HCC patients (P=0.004, P=0.014). Furthermore, in TCGA database, the expression level of CXCL10 and CXCR3 was positively correlated both in HCC tumor tissues and matched non-tumor tissues (r=0.584, P<0.001; r=0.776, P<0.001). The qPCR assay showed that the expression of CXCL10 in HBV-related HCC tumor tissues was significantly higher than those in normal liver tissues [0.479(0.223, 1.094) vs. 0.131(0.106, 0.159), P=0.010], and the expression in HBV-related non-tumor tissues was also significantly higher than those in normal liver tissues [0.484(0.241, 0.846) vs. 0.131(0.106, 0.159), P<0.001]. The same was true as CXCR3 [0.011(0.006, 0.019) vs. 0.002(0.001, 0.004), P=0.004; 0.016(0.011, 0.021) vs. 0.002(0.001, 0.004), P<0.001]. However there was no significant difference of CXCL10 and CXCR3 between tumor tissues and matched non-tumor tissues (P=1.000, P=0.374).Conclusion: Expression of CXCL10 was up-regulated in HCC tissues, expression of CXCR3 was down-regulated in HBV-related HCC tissues, and the higher expression of both genes was correlated with better overall survival in HCC patients.

Cite this article

Jing ZHANG , Jie CHEN , Gui-wen GUAN , Ting ZHANG , Feng-min LU , Xiang-mei CHEN . Expression and clinical significance of chemokine CXCL10 and its receptor CXCR3 in hepatocellular carcinoma[J]. Journal of Peking University(Health Sciences), 2019 , 51(3) : 402 -408 . DOI: 10.19723/j.issn.1671-167X.2019.03.005

References

[1] Joliat GR, Allemann P, Labgaa I , et al. Treatment and outcomes of recurrent hepatocellular carcinomas[J]. Langenbecks Arch Surg, 2017,402(5):737-744.
[2] El-Serag HB, Rudolph KL . Hepatocellular carcinoma: epidemio-logy and molecular carcinogenesis[J]. Gastroenterology, 2007,132(7):2557-2576.
[3] Hong TP, Gow P, Fink M , et al. Novel population-based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is needed[J]. Hepatology, 2016,63(4):1205-1212.
[4] Elia G, Fallahi P . Hepatocellular carcinoma and CXCR3 chemokines: a narrative review[J]. Clin Ter, 2017,168(1):e37-e41.
[5] 中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版)[J]. 临床肝胆病杂志, 2011,27(11):1141-1159.
[6] Kamil F, Rowe JH . How does the tumor microenvironment play a role in hepatobiliary tumors?[J]. J Gastrointest Oncol, 2018,9(1):180-195.
[7] Tokunaga R, Zhang W, Naseem M , et al. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation:a target for novel cancer therapy[J]. Cancer Treat Rev, 2018,63:40-47.
[8] Ren T, Zhu L, Cheng M . CXCL10 accelerates EMT and metastasis by MMP-2 in hepatocellular carcinoma[J]. Am J Transl Res, 2017,9(6):2824-2837.
[9] Hirano S, Iwashita Y, Sasaki A , et al. Increased mRNA expression of chemokines in hepatocellular carcinoma with tumor-infiltrating lymphocytes[J]. J Gastroenterol Hepatol, 2007,22(5):690-696.
[10] Chew V, Chen J, Lee D , et al. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma[J]. Gut, 2012,61(3):427-438.
[11] Ding Q, Xia Y, Ding S , et al. An alternatively spliced variant of CXCR3 mediates the metastasis of CD133 + liver cancer cells induced by CXCL9 [J]. Oncotarget, 2016,7(12):14405-14414.
[12] 任颖, 阚云珍, 孔令非 . 靶向沉默CXCR3对肝癌细胞恶性增殖的作用研究[J]. 中华肝脏病杂志, 2018,26(7):508-512.
[13] Billottet C, Quemener C, Bikfalvi A . CXCR3, a double-edged sword in tumor progression and angiogenesis[J]. Biochim Biophys Acta, 2013,1836(2):287-295.
Outlines

/